Industry News
Johnson & Johnson Vision Launches New Contact Lens Innovation
Johnson & Johnson Vision Care recently announced the launch of its newest innovation, ACUVUE® OASYS MAX 1-DAY contact lenses and ACUVUE® OASYS MAX 1-Day MULTIFOCAL contact lenses for presbyopia. Designed with an unprecedented combination of new technologies to help meet the needs of digitally intense lifestyles: TearStable™ Technology and OptiBlue™ light filter. TearStable™ Technology is designed to maximize tear-film stability and lock in moisture for exceptional all-day comfort.1,2 The OptiBlue™ light filter has the highest level blue-violet filter in the industry at 60%, to reduce light scatter for exceptional visual clarity, day to night. In addition, ACUVUE® OASYS MAX 1-Day lenses block 99.9% UVA rays and 100% UVB rays.
"Life has changed, post-pandemic. With more time spent on digital devices,6 we designed these contact lenses by listening to patients and eye care professionals' feedback to address lifestyle requirements and help prevent dry and tired eyes from becoming normalized," said John Buch, OD, Senior Principal Research Optometrist, Johnson & Johnson Vision. "Our new ACUVUE® OASYS MAX 1-Day contact lenses help reduce discomfort by providing visual clarity with new technologies to filter blue-violet light, which comes from many sources, including digital screens and travels in short wavelengths and scatters more which can lead to eye discomfort and quality of vision."
Adults are now spending 13+ hours a day on digital devices, a 35% increase since 2019. When looking at a digital screen, you blink 60% less, which can destabilize the tear film, impacting comfort and vision. Blue-violet light scatters from digital screens, fluorescent/LED lights and the sun, which can impact visual clarity. These demands are even more troubling for aging eyes. While digital screen use destabilizes the tear film at all ages, the tear film breaks down 50% faster by age 50 and may exacerbate the feelings of dry eye and impact consistency of vision. Meanwhile, light scatter doubles by age 60, resulting in increased visual artifacts (starbursts, halos), impacting distance vision, and contributing to decreased ability to drive at night or read in dim light.
For patients with presbyopia (a condition that happens to everyone around age 40 negatively impacting near vision, particularly in dim light), ACUVUE® OASYS MAX 1-Day MULTIFOCAL contact lenses provide crisp, clear vision at all distances and in all lighting conditions, as well as all-day comfort. The lenses combine the same two powerful technologies – TearStable™ Technology and the OptiBlue™ light filter – plus PUPIL OPTIMIZED DESIGN technology, which tailors 100% of parameters to pupil size variations across both age and refraction compared to less than 2% for the leading competitor, for exceptionally effortless vision. This is the same technology that is available across all ACUVUE® Multifocal contact lenses.
"I've witnessed more patients facing symptoms related to a destabilized tear film such as dryness and inconsistent vision due to our increasingly digital lifestyles. It's important for all contact lens users to have the latest innovative treatment options available to help address comfort and clarity to meet their lifestyle requirements," said Luis Rojas, OD, co-founder of DeNovo Eye. "ACUVUE® OASYS MAX 1-Day uses innovative technology, designed to maximize tear film stability and reduce light scatter to maintain increased visual clarity and all-day comfort."
ACUVUE® OASYS MAX 1-Day builds on the ACUVUE® OASYS portfolio of products, which is unbeaten in comfort across 31 clinical trials. In clinical trials of ACUVUE® OASYS MAX 1-Day, 90% of wearers reported all-day comfort and a reduction in tired eyes from digital devices, with nearly 100% reporting clear, reliable vision.
Earlier this year, ACUVUE® OASYS MAX 1-Day and ACUVUE® OASYS MAX 1-Day MULTIFOCAL received U.S. Food & Drug Administration (FDA) clearance, Health Canada approval and completed CE Mark activities for its latest contact lens innovation.
